The approval of Evrysdi (risdiplam) was based on 2 main studies in more than 450 people with SMA aged 2 months to 25 years. According to the study results published: Type 1 SMA Evrysdi helped infants achieve a key motor milestone: Evrysdi (risdiplam) helped infants survive without permanent breathing support: Type 2 and 3 SMA Motor neuron function improved in children and adults. Evrysdi increased motor function with 1.6 points, as measured using the MFM32 scale. The score increased 1.36 points for those taking Evrysdi compared with a 0.19-point decrease for those not taking Evrysdi.